Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heptagem is a combination pharmaceutical product formulated as an oral syrup, marketed by Gempharr Healthcare. It is primarily used as a hepatoprotective agent and a digestive aid to manage liver disorders and associated symptoms. The formulation typically consists of tricholine citrate and sorbitol. Tricholine citrate acts as a lipotropic agent by providing choline, a precursor for phosphatidylcholine (lecithin), which is essential for mobilizing fats from the liver and maintaining hepatic cell membrane integrity. Sorbitol functions as an osmotic laxative by increasing water retention in the intestinal lumen and also acts as a cholagogue, stimulating the gallbladder to release bile. Together, these components help prevent fatty infiltration of the liver, improve digestion, and relieve chronic constipation related to hepatic insufficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tricholine citrate + sorbitol.